#78 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
Clinicians need this evidence to counter patient beliefs and marketing claims that cannabis treats depression, anxiety, and PTSD, conditions for which established pharmacotherapies and psychotherapies have demonstrated efficacy. The lack of supportive evidence should inform shared decision-making conversations and prevent patients from delaying or replacing evidence-based treatments with unproven alternatives. Given that 27% of people report using cannabis for these conditions, clinicians must be equipped to discuss both the absence of clinical benefit and potential harms including cannabinoid hyperemesis syndrome and cannabis use disorder.
# Clinical Summary A recent systematic review found insufficient evidence to support the efficacy of medicinal cannabis for treating depression, anxiety, or post-traumatic stress disorder, despite growing patient interest in cannabis as a therapeutic option for these conditions. This conclusion is particularly significant given that approximately 27% of cannabis users cite mental health symptom management as their primary motivation for use, creating a substantial gap between patient expectations and clinical evidence. The lack of robust evidence reflects limitations in current research, including small sample sizes, heterogeneous cannabis formulations, and variable dosing regimens that complicate meaningful comparisons. For clinicians, this finding underscores the importance of counseling patients that cannabis should not be considered an evidence-based treatment for these psychiatric conditions and that established therapies such as antidepressants, cognitive behavioral therapy, and other psychotherapies remain the standard of care. Patients currently using cannabis for depression, anxiety, or PTSD should be encouraged to discuss their symptoms with their healthcare provider to ensure access to interventions with demonstrated effectiveness rather than relying on unproven cannabis-based approaches.
“What we’re seeing is a significant gap between patient expectations and the actual evidence base, and as clinicians we have an obligation to be honest about that rather than offer false hope based on anecdotal reports or industry enthusiasm.”
🧠 While cannabinoid research has expanded considerably, the absence of robust evidence for cannabis efficacy in depression, anxiety, and PTSD should inform clinical conversations with patients seeking this treatment. The high prevalence of cannabis use among individuals with these conditions (27% in some populations) likely reflects both symptom relief perception and limited access to evidence-based alternatives rather than proven therapeutic benefit. Clinicians should acknowledge that short-term subjective improvements in anxiety symptoms may occur through various mechanisms including placebo effects, behavioral changes, or altered risk perception, yet these do not necessarily translate to sustained clinical benefit or disease modification. Additionally, cannabis use can complicate the clinical picture through drug interactions, exacerbation of psychotic symptoms in vulnerable populations, and potential for dependence, making comprehensive risk-benefit discussion essential. In practice, patients inquiring about cannabis for these indications should be counseled that current evidence supports psychotherapy and pharmacotherapy as first-line treatments,
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: